title: The old is new: Lipid therapy and CKD.
abstract: On the heels of the 2013 American College of Cardiology/American Heart Association guidelines for lipid therapy, Kidney Disease: Improving Global Outcomes (KDIGO) released updated guidelines for managing hyperlipidemia in patients with chronic kidney disease. This article describes the KDIGO guidelines' focus on individualized cardiovascular risk assessment and treatment.
authors.affiliation: Darlene Dobkowski practices at Holy Name Medical Center in Teaneck, N.J. Mandy E. Thompson practices nephrology at Denver (Colo.) Health Hospital. The authors have disclosed no potential conflicts of interest, financial or otherwise.
authors.forename: Darlene
authors.initials: D
authors.lastname: Dobkowski
authors.forename: Mandy E
authors.initials: ME
authors.lastname: Thompson
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology*; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology / Q000628:therapy*; D008055:Lipids / Q000097:blood; D017410:Practice Guidelines as Topic; D051436:Renal Insufficiency, Chronic / Q000150:complications*; D018570:Risk Assessment / Q000379:methods / Q000592:standards*; D012307:Risk Factors; D014481:United States
chemical_list: D008055:Lipids